Study guide
3.4 Neurologic Disease Progression
Certified Hospice and Palliative Nurse CHPN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Fees, Windows, and Retakes 1.3 Scoring, Test-Day Rules, and Remote Proctoring 1.4 Recertification: HPAR and the Situational Judgment Exercise
2 Chapter 2: Assessment, Goals, and Care Planning
2.1 Goals of Care and Shared Decision Making 2.2 Interdisciplinary Care Planning and Ongoing Evaluation 2.3 Prognostic and Functional Assessment Tools 2.4 Levels of Care and Care-Setting Transitions
3 Chapter 3: Life-Limiting Disease Progression I
3.1 Cancer, Hematologic, and Paraneoplastic Complications 3.2 Heart Failure and Cardiac Disease Progression 3.3 Pulmonary Disease Progression 3.4 Neurologic Disease Progression
4 Chapter 4: Disease Progression II and Imminent Death
4.1 Dementia, Frailty, and Feeding Decisions 4.2 Renal, Hepatic, and Endocrine Trajectories 4.3 Indicators of Imminent Death
5 Chapter 5: Pain Assessment
5.1 Pain Types, Etiology, and Syndromes 5.2 Verbal and Nonverbal Pain Assessment and Scales 5.3 Factors That Influence the Pain Experience
6 Chapter 6: Pharmacologic Pain Management
6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity 6.2 Adjuvant Analgesics 6.3 Titration, Baseline Dosing, and Breakthrough Pain 6.4 Equianalgesic Conversion and Route Changes
7 Chapter 7: Nonpharmacologic Pain and Opioid Safety
7.1 Nonpharmacologic Pain Interventions 7.2 Complementary and Integrative Pain Therapies 7.3 Opioid Adverse Effects, Neurotoxicity, and Rotation
8 Chapter 8: Neurological, Cardiovascular, and Respiratory Symptoms
8.1 Neurological Symptoms 8.2 Delirium and Terminal Restlessness 8.3 Cardiovascular Symptoms 8.4 Respiratory Symptoms: Dyspnea, Cough, and Secretions
9 Chapter 9: Gastrointestinal, Genitourinary, and Musculoskeletal Symptoms
9.1 Gastrointestinal Symptoms 9.2 Genitourinary Symptoms 9.3 Musculoskeletal Symptoms
10 Chapter 10: Skin, Metabolic, Hematologic, and Psychospiritual Symptoms
10.1 Skin and Mucous Membrane Symptoms 10.2 Nutritional and Metabolic Symptoms 10.3 Immune and Hematologic Symptoms 10.4 Psychosocial, Emotional, and Spiritual Symptom Burden
11 Chapter 11: Advance Care Planning, Benefits, and Safety
11.1 Advance Care Planning and Life-Sustaining Therapies 11.2 Hospice and Palliative Benefits under Medicare, Medicaid, and Private Insurance 11.3 Patient Safety: Environmental, Physical, and Socioemotional
12 Chapter 12: Communication, Culture, and Psychosocial Support
12.1 Communication Techniques, Barriers, and Family Meetings 12.2 Cultural Humility and Spiritual Needs 12.3 Psychosocial Needs and IDG Participation
13 Chapter 13: Caregiver Education and Medication Management
13.1 Medication Management and Controlled Substances 13.2 Caregiver and Family Self-Care 13.3 Teaching End-Stage Disease, Pain, and Symptom Plans 13.4 Caregiver Skills, DME, Supplies, and Services
14 Chapter 14: Grief, Death, and End-of-Life Ethics
14.1 Grief, Loss, and Bereavement 14.2 Support at the Time of Death and Post-Mortem Care 14.3 Ethical Issues Related to End of Life
15 Chapter 15: Medicare Hospice Compliance and National Standards
15.1 Medicare Hospice Benefit and Conditions of Participation 15.2 Hospice Eligibility, Admission, and Recertification 15.3 National Hospice and Palliative Care Standards 15.4 National Consensus Project Clinical Practice Guidelines
16 Chapter 16: Legal, Professional Practice, Quality, and Policy
16.1 Legal Regulations: CMS, HIPAA, and OSHA 16.2 Professional Boundaries and Ethics 16.3 QAPI, Self-Care, and Precepting 16.4 Policy, Delivery, and Reimbursement Trends
3.4 Neurologic Disease Progression
Key Takeaways Explain This Topic AI
Large middle-cerebral-artery stroke and hemorrhagic versus ischemic paths drive feeding-tube and aspiration decisions; a tube does not reliably prevent aspiration pneumonia and must match goals of care.
ALS deaths are usually from respiratory failure. Start advance care planning and communication boards while speech is intact; NIV and secretion plans dominate late care, and riluzole is only modestly disease-modifying.
Late Parkinson disease brings rigidity, aspiration, and psychosis that often tracks dopaminergic dose. Recurrent aspiration-pneumonia cycles are a decline signal. Multiple sclerosis can reach the same infection-and-swallow end stage.
Delirium is a later CHPN chapter. In neurologic disease, treat new confusion as a complication signal—infection, hypoxia, medication, or stroke extension—without dumping the full delirium protocol here.
Last updated: August 2026
Neurologic trajectories without turning this into the delirium chapter
Domain 1.C on the 150-item HPCC CHPN exam includes neurologic life-limiting disease because swallowing, breathing, and communication fail in patterns you can name. This section covers stroke , amyotrophic lateral sclerosis (ALS) , Parkinson disease , and multiple sclerosis (MS) . Delirium is a later chapter. Here, new confusion is only a complication signal —ask what just changed (aspiration, urine, hypoxia, a dopaminergic increase, stroke extension)—then return to the disease curve.
Stroke: large MCA, hemorrhagic versus ischemic, feeding tubes
A large middle-cerebral-artery (MCA) infarct can produce dense hemiplegia, aphasia or neglect, gaze preference, and, in some hemispheres, malignant MCA edema with herniation risk in the first days. Early mortality and devastating disability are why families are asked about intubation, hemicraniectomy, and artificial nutrition while the patient cannot speak.
Ischemic stroke is a clot or hypoperfusion story: some recovery is possible over days to weeks, which makes hospice timing harder. Hemorrhagic stroke (intracerebral or subarachnoid) is often more sudden, with headache, collapse, and higher early mortality. Neither pattern makes a feeding tube automatic.
Percutaneous feeding tubes do not reliably prevent aspiration pneumonia . Patients still aspirate oral secretions. Tubes can increase restraint use, diarrhea, and the number of “we must treat the pneumonia” cycles. The CHPN RN teaches that a tube is a goals-of-care device , not an anti-pneumonia device. Comfort feeding, oral care, and accepting infection risk can be the concordant plan after a devastating MCA or a recurrent hemorrhage. If the goal is still time and the swallow may recover, a time-limited nasogastric trial in a hospital or skilled setting is more honest than an immediate percutaneous tube “so he will not starve.” Starvation language is a family fear; explain that dying brain injury takes appetite and swallow together, and that fluids can increase secretions and edema.
Aphasia after a left MCA stroke is why communication boards , yes/no eye blink, and partner-assisted scanning belong on the care plan from day one—not after the family has already signed a tube consent they do not understand.
ALS: respiratory failure, NIV, secretions, riluzole, early planning
ALS is progressive motor-neuron loss. Death is usually respiratory failure , not a sudden arrhythmia. The CHPN trajectory is falling vital capacity, orthopnea, weak cough, secretion pooling, and daytime hypercapnia. NIV (often bilevel) can both palliate dyspnea and extend survival while the patient still wants time. It becomes a burden when the patient cannot tolerate the mask, cannot clear secretions, or has chosen to stop ventilatory support. Invasive tracheostomy ventilation is a separate, value-laden decision; many U.S. patients decline it. The CHPN RN does not present tracheostomy as the only loyal option.
Riluzole is disease-modifying with a modest effect on survival. It is not a rescue drug at hospice election and does not replace a respiratory plan. Other disease-directed agents may appear on home medication lists; none reverse respiratory failure. Gastrostomy in ALS is about nutrition and pill burden while swallow is failing, with the same honesty as stroke: it does not erase aspiration of saliva.
Advance care planning must start while communication is intact. That is the ALS-specific CHPN rule. Waiting until anarthria to ask about NIV, hospitalization, or feeding tubes leaves families guessing. Communication boards , eye-gaze systems, and low-tech letter boards are clinical equipment, not occupational-therapy extras.
Secretion management is daily ALS work: weak cough, sialorrhea, choking on thin liquids. Positioning, cough-assist devices in some programs, and later-chapter antisecretory drugs matter. Repeated deep suction as the default turns the home into an intensive-care unit the patient did not elect.
Parkinson disease, MS, communication, and aspiration cycles
Late Parkinson disease is rigidity, immobility, falls, dementia in many, and a weak swallow. Aspiration is the infection engine. Visual hallucinations and psychosis often worsen when dopaminergic doses (carbidopa-levodopa, dopamine agonists) climb to chase rigidity. The CHPN move is to collaborate on reducing the dopaminergic burden while still treating painful rigidity as goals allow—not to add another agonist “for the hallucinations.” New confusion here is a complication signal (meds, infection, constipation, metabolic change), not a cue to paste in the full delirium protocol from a later chapter.
MS , especially secondary progressive disease, can reach the same end: bedbound spasticity, neurogenic bladder, recurrent urinary infection, and aspiration. Relapsing-remitting MS in a young adult is not the usual hospice picture until the progressive phase or a catastrophic brainstem event.
Aspiration-pneumonia cycles are the shared late pathway for stroke, ALS, Parkinson disease, and MS. Each treated cycle can be a reasonable rescue if the goal is time. Each cycle also marks decline. Antibiotics, hospital transfer, and suction intensity are goal questions. The CHPN RN names the cycle so the fifth pneumonia is not framed as a surprise failure of nursing.
Disease Dominant late pattern CHPN planning trap
Large MCA stroke Disability, aphasia/neglect, possible malignant edema Feeding tube sold as pneumonia prevention
- Hemorrhagic stroke Sudden collapse, high early mortality Assuming a long ischemic-style recovery window
- ALS Respiratory failure, NIV, secretions Waiting to plan until speech is gone; treating riluzole as a cure
Parkinson disease Rigidity, aspiration, dopaminergic psychosis Raising dopamine agonists to treat hallucinations
MS Progressive disability, infection, swallow failure Treating every relapsing history as a hospice-ineligible disease
Use communication supports in every one of these diseases when speech, language, or motor control fails. The board, the blink, and the documented yes/no method are how you keep consent real as the trajectory closes.